neu/ERBB2 Cooperates with p53-172H during Mammary Tumorigenesis in Transgenic Mice

REFERENCES

• Ali, I. U., G. Merlo, R. Gallahan, and R. Lidereau. 1989. The amplification unit on chromosome 11q13 in aggressive primary human breast tumors entails the bcl-1, int-2 and hst loci. Oncogene 4:89–92.
   PubMed Web of Science ®Google Scholar
• Bayna, E.M., and J.M. Rosen. 1990. Tissue-specific, high level expression of the rat whey acidic protein gene in transgenic mice. Nucleic Acids Res. 18:2977–2985.
   PubMedGoogle Scholar
• Bienz, B., R. Zakut-Houri, D. Givol, and M. Oren. 1984. Analysis of the gene coding for the murine cellular tumor antigen p53. EMBO J. 3:2179–2183.
   PubMed Web of Science ®Google Scholar
• Blaydes, J. P., M. Shlumberger, D. Wynford-Thomas, and F. S. Wyllie. 1995. Interaction between p53 and TGF beta 1 in control of epithelial cell proliferation. Oncogene 10:307–317.
   PubMedGoogle Scholar
• Caron de Fromental, C., and T. Soussi. 1992. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4:1–15.
   PubMed Web of Science ®Google Scholar
• Cheng, J., and M. Haas. 1990. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol. Cell. Biol. 10:5502–5509.
   PubMed Web of Science ®Google Scholar
• Chin, K.-V., K. Ueda, I. Pastan, and M. M. Gottesman. 1992. Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255:459–462.
   PubMed Web of Science ®Google Scholar
• Cho, Y., S. Gorina, P. D. Jeffrey, and N. P. Pavletich. 1994. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265:346–355.
   PubMed Web of Science ®Google Scholar
• Crawford, L., and P. Lamb. 1986. Characterization of the human p53 gene. Mol. Cell. Biol. 6:1379–1385.
   PubMedGoogle Scholar
• Davidoff, A. M., P. A. Humphrey, J. D. Iglehart, and J. R. Marks. 1991. Genetic basis for p53 overexpression in human breast cancer. Proc. Natl. Acad. Sci. USA 88:5006–5010.
   PubMed Web of Science ®Google Scholar
• Dittmer, D., S. Pati, G. Zambetti, S. Chu, A. K. Teresky, M. Moore, C. Finlay, and A. J. Levine. 1993. Gain of function mutations in p53. Nat. Genet. 4:42–46.
   PubMed Web of Science ®Google Scholar
• Eliyahu, D., A. Raz, P. Gruss, D. Givol, and M. Oren. 1984. Participation of p53 cellular tumor antigen in transformation of normal embryonic cells. Nature 312:646–649.
   PubMed Web of Science ®Google Scholar
• Ewen, M. E., C. J. Oliver, H. K. Sluss, S. J. Miller, and D. S. Peeper. 1995. p53-dependent repression of cdk4 translation in TGF-beta-induced G1 cell-cycle arrest. Genes Dev. 9:204–217.
   PubMed Web of Science ®Google Scholar
• Finlay, C. A., P. W. Hinds, and A. J. Levine. 1989. The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093.
   PubMed Web of Science ®Google Scholar
• Franch, H. A., J. A. Shay, R. J. Alpern, and P. A. Preisig. 1995. Involvement of pRB family in TGF beta-dependent epithelial cell hypertrophy. J. Cell Biol. 129:245–254.
   PubMedGoogle Scholar
• Fusakawa, K., T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Woude. 1996. Abnormal centrosome amplification in the absence of p53. Science 271:1744–1747.
   PubMedGoogle Scholar
• Gerwin, B. I., E. Spillare, K. Forrester, T. A. Lehman, J. Kispert, J. A. Welsh, A. M. A. Pfeifer, J. F. Lechner, S. J. Baker, B. Vogelstein, and C. C. Harris. 1992. Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA 89:2759–2763.
   PubMed Web of Science ®Google Scholar
• Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379:88–91.
   PubMed Web of Science ®Google Scholar
• Greenhalgh, D. A., X.-J. Wang, L. A. Donehower, and D. R. Roop. 1996. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, V-fos, or human transforming growth factor alpha. Cancer Res. 56:4413–4423.
   PubMedGoogle Scholar
• Guy, S. T., M. A. Webster, M. Schaller, T.J. Parsons, R. D. Cardiff, and W.J. Muller. 1992. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89:10578–10582.
   PubMed Web of Science ®Google Scholar
• Harvey, M., A. T. Sands, R. S. Weiss, M. E. Hegi, R. W. Wiseman, P. Pantazis, B. C. Giovanella, M. A. Tainsky, A. Bradley, and L. A. Donehower. 1993. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8:2457–2467.
   PubMed Web of Science ®Google Scholar
• Harvey, M., H. Vogel, D. Morris, A. Bradley, A. Bernstein, and L. A. Done-hower. 1995. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9:305–311.
   PubMed Web of Science ®Google Scholar
• Hedley, D. W., M. L. Friedlander, I. W. Taylor, C. A. Rugg, and E. A. Musgrove. 1983. Method for analysis of cellular DNA content of parafinembedded pathological material using flow cytometry. J. Histochem. Cytochem. 31:1333–1335.
   PubMed Web of Science ®Google Scholar
• Hinds, P. W., C. A. Finlay, R. S. Quartin, S. J. Baker, E. R. Fearon, B. Vogelstein, and A. J. Levine. 1990. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the “hot spot” mutant phenotypes. Cell Growth Differ. 1:571–580.
   PubMedGoogle Scholar
• Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49–53.
   PubMed Web of Science ®Google Scholar
• Horak, E., K. Smith, L. Bromley, S. LeJeune, M. Greenall, D. Lane, and A. L. Harris. 1991. Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6:2277–2284.
   PubMedGoogle Scholar
• Hsiao, M., J. Low, E. Dorn, D. Ku, P. Pattengale, J. Yeargin, and M. Haas. 1994. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am. J. Pathol. 145:702–714.
   PubMed Web of Science ®Google Scholar
• Humphreys, R. C., M. Krajewska, S. Krnacik, R. Jaeger, H. Weiher, S. Krajewski, J. C. Reed, and J. M. Rosen. 1996. Apoptosis in the terminal end bud of the murine mammary gland: a mechanism of ductal morphogenesis. Development, 122:4013–4022.
   PubMedGoogle Scholar
• Hynes, N. E., and D. F. Stern. 1994. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta Rev. Cancer 1198:165–184.
   PubMed Web of Science ®Google Scholar
• Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304–6311.
   PubMed Web of Science ®Google Scholar
• Kern, S. E., K. W. Kinzler, S. J. Baker, J. M. Nigro, V. Rotter, A. J. Levine, P. Friedman, C. Prives, and B. Vogelstein. 1991. Mutated p53 binds DNA abnormally in vitro. Oncogene 6:131–136.
   PubMed Web of Science ®Google Scholar
• Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, and B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827–832.
   PubMed Web of Science ®Google Scholar
• Kieser, A., H. A. Weich, G. Brandner, D. Marme, and W. Kolch. 1994. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963–969.
   PubMed Web of Science ®Google Scholar
• Ko, L. J., and C. Prives. 1996. p53: puzzle and paradigm. Genes Dev. 10:1054–1072.
   PubMed Web of Science ®Google Scholar
• Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491–7495.
   PubMed Web of Science ®Google Scholar
• Kumar, R., D. Medina, and S. Sukumar. 1990. Activation of H-Ras oncogene in preneoplastic mouse mammary tissue. Oncogene 5:1271–1277.
   PubMedGoogle Scholar
• Lee, E. Y.-H., H. To, J. Y. Shew, R. Bookstein, P. Scully, and W.-H. Lee. 1988. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241:218–221.
   PubMed Web of Science ®Google Scholar
• Lee, K.-F., F. J. DeMayo, S. H. Aliee, and J. M. Rosen. 1988. Tissue-specific expression of the rat beta-casein gene in transgenic mice. Nucleic Acids Res. 16:1027–1041.
   PubMed Web of Science ®Google Scholar
• Li, B., F. S. Kittrell, D. Medina, and J. M. Rosen. 1995. Delay of dimethylbenz[a]anthracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein. Mol. Carcinog. 13:75–83.
   Google Scholar
• Li, B., N. Greenberg, L. C. Stephens, R. Meyn, D. Medina, and J. M. Rosen. 1994. Preferential overexpression of a 172Arg-Leu mutant p53 in the mammary gland of transgenic mice results in altered lobuloalveolar development. Cell Growth Differ. 5:711–721.
   PubMedGoogle Scholar
• Li, B., D. Medina, and J. M. Rosen. Unpublished data.
   Google Scholar
• Li, B., R. Murphy, R. Lauririca, F. S. Kittrell, D. Medina, and J. M. Rosen. Unpublished data.
   Google Scholar
• Li, M., J. Hu, K. Heermeier, L. Henninghausen, and P. Furth. 1996. Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53-independent pathways. Cell Growth Differ. 7:13–20.
   PubMedGoogle Scholar
• Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923–935.
   PubMed Web of Science ®Google Scholar
• Lowe, S. W., E. M. Schmitt, S. W. Smith, B. A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847–849.
   PubMed Web of Science ®Google Scholar
• Macleod, K. F., N. Sherry, G. Hannon, D. Beach, T. Tokino, K. Kinzler, B. Vogelstein, and T. Jacks. 1995. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 9:935–944.
   PubMed Web of Science ®Google Scholar
• Medina, D. 1974. Mammary tumorigenesis in chemical carcinogen-treated mice. I. Incidence in Balb-c and C57BL mice. J. Natl. Cancer Inst. 53:213–221.
   PubMed Web of Science ®Google Scholar
• Metz, T., A. W. Harris, and J. M. Adams. 1995. Absence ofp53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes. Cell 82:29–36.
   PubMedGoogle Scholar
• Milner, J., and E. A. Medcalf. 1991. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765–774.
   PubMed Web of Science ®Google Scholar
• Miyashita, T., and J. C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293–299.
   PubMed Web of Science ®Google Scholar
• Muller, W. J. et al. Unpublished results.
   Google Scholar
• Muller, W. J., C. L. Arteaga, S. K. Muthuswamy, P. M. Siegel, M. A. Webster, R. D. Cardiff, K. S. Meise, F. Li, S. A. Halter, and R. J. Coffey. 1996. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol. Cell. Biol. 16:5726–5736.
   PubMed Web of Science ®Google Scholar
• Muller, W. J., E. Sinn, P. K. Pattengale, R. Wallace, and P. Leder. 1988. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115.
   PubMed Web of Science ®Google Scholar
• Nigro, J. M., S. J. Baker, A. C. Preisinger, J. M. Jessup, R. Hostetter, K. Cleary, S. H. Bigner, N. Davidson, S. Baylin, P. Devilee, T. Glover, F. S. Collins, A. Weston, R. Modali, C. C. Harris, and B. Vogelstein. 1989. Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705–708.
   PubMed Web of Science ®Google Scholar
• Ozbun, M. A., and J. S. Butel. 1995. Tumor suppressor p53 mutations and breast cancer: a critical analysis. Adv. Cancer Res. 66:71–141.
   PubMed Web of Science ®Google Scholar
• Pittius, C. W., L. Sankaran, Y. J. Topper, and L. Hennighausen. 1988. Comparison of the regulation of the whey acidic protein gene with that of a hybrid gene containing the whey acidic protein gene promoter i transgenic mice. Mol. Endocrinol. 2:1027–1032.
   PubMedGoogle Scholar
• Ponchel, F., A. Puisieux, E. Tabone, J. P. Michot, G. Froschl, A. Morel, T. Frebourg, B. Fontaniere, F. Oberhammer, and M. Ozturk. 1994. Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res. 54:2064–2068.
   PubMed Web of Science ®Google Scholar
• Prosser, J., A. M. Thompson, G. Cranson, and H. J. Evans. 1990. Evidence that p53 behaves as a tumour suppressor gene in sporatic breast tumours. Oncogene 5:1573–1579.
   PubMedGoogle Scholar
• Purdie, C., D. J. Harrison, A. Peter, L. Dobbie, S. White, S. E. M. Howie, D. M. Salter, C. C. Bird, A. H. Wyllie, M. L. Hooper, and A. R. Clarke. 1994. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 9:603–609.
   PubMed Web of Science ®Google Scholar
• Reiss, M., V. F. Vellucci, and Z. Zhou. 1993. Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes. Cancer Res. 53:899–904.
   PubMed Web of Science ®Google Scholar
• Rosen, N., J. B. Bolen, A. M. Schwartz, P. Cohen, V. DeSeau, and M. A. Israel. 1986. Analysis of pp60 c-src protein kinase activity in human tumor cell lines and tissues. J. Biol. Chem. 261:13754–13759.
   PubMed Web of Science ®Google Scholar
• Rovinski, B., and S. Benchimol. 1988. Immortalization of rat embryo fibroblasts by the cellular p53 oncogene. Oncogene 2:445–452.
   PubMed Web of Science ®Google Scholar
• Sabbatini, P., J. Lin, A. J. Levine, and E. White. 1995. Essential role for p53-mediated transcription in E1A-induced apoptosis. Genes Dev. 9:2184–2192.
   PubMed Web of Science ®Google Scholar
• Siegel, P. M., D. L. Dankort, W. R. Hardy, and W. J. Muller. 1994. Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol. Cell. Biol. 14:7068–7077.
   PubMed Web of Science ®Google Scholar
• Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and R. L. McGuire. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/Neu oncogene. Science 235:177–182.
   PubMed Web of Science ®Google Scholar
• Slamon, D. J., W. Godolphin, L. A. Jones, J. A. Holt, S. C. Wong, D. E. Keith, W. J. Levin, S. G. Stuart, J. Udore, A. Ullrich, and M. F. Press. 1989. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707–712.
   PubMed Web of Science ®Google Scholar
• Symonds, H., L. Krall, L. Remington, M. Saenz-Robles, S. Lowe, T. Jacks, and T. Van Dyke. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703–711.
   PubMed Web of Science ®Google Scholar
• Takahashi, T., B. Eitzman, and N. L. Bossert. 1994. Transforming growth factor b1, b2, and b3 messenger RNA and protein expression in mouse uterus and vagina during estrogen-induced growth: a comparison to other estrogen-regulated genes. Cell Growth Differ. 5:919–935.
   PubMedGoogle Scholar
• Tsukada, T., Y. Tomooka, S. Takai, Y. Ueda, S. Nishikawa, T. Yagi, T. Tokunaga, N. Takeda, Y. Suda, S. Abe, I. Matsuo, Y. Ikawa, and S. Aizawa. 1993. Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8:3313–3322.
   PubMed Web of Science ®Google Scholar
• Varley, J. M., W. J. Brammar, D. P. Lane, J. E. Swallow, C. Dolan, and R. A. Walker. 1991. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 6:413–421.
   PubMed Web of Science ®Google Scholar
• Waldman, T., C. Lengauer, K. W. Kinzler, and B. Vogelstein. 1996. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 381:713–716.
   PubMed Web of Science ®Google Scholar
• Wang, X.-J. et al. Personal communication.
   Google Scholar
• Williams, A. C., S. J. Browne, A. M. Manning, P. Daffada, T. J. Collard, and C. Paraskeva. 1994. Transfection and expression of mutant p53 protein does not alter the in vivo or in vitro growth characteristics of the AA/C1 human adenoma derived cell line, including sensitivity to transforming growth factor-beta 1. Oncogene 9:1479–1485.
   PubMedGoogle Scholar
• Wyllie, F. S., T. Dawson, J. A. Bond, P. Goretzki, S. Game, S. Prime, and D. Wynford-Thomas. 1991. Correlated abnormalities of transforming growth factor-beta 1 response and p53 expression in thyroid epithelial cell transformation. Mol. Cell. Endocrinol. 76:13–21.
   PubMedGoogle Scholar
• Yamamoto, M., Y. Maehara, Y. Sakaguchi, T. Kusumoto, Y. Ichiyoshi, and K. Sugimachi. 1996. Transforming growth factor-beta 1 induces apoptosis in gastric cancer cells through a p53-independent pathway. Cancer 77:1628–1633.
   PubMedGoogle Scholar
• Yonish-Rouach, E., D. Resnitsky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wildtype p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345–347.
   PubMed Web of Science ®Google Scholar